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Purpose: This post hoc analysis assessed switching to ezetimibe/simvastatin 10/20 mg vs doubling the baseline
statin dose to simvastatin 40 mg or atorvastatin 20 mg or switching to rosuvastatin 10 mg in subgroups of obese
(BMI ≥30 kg/m2) and non-obese (BMI <30 kg/m2) diabetic subjects.
Methods: This was a randomized, double-blind, 12-week study of adults 18–79 years with cardiovascular disease
with low-density lipoprotein cholesterol (LDL-C) ≥70 and ≤160 mg/dl. Percent change in LDL-C and other lipids
was estimated.
Results: In obese subjects (n = 466), percent changes in LDL-C and most other lipids were greater with ezetimibe/
simvastatin vs doubling the baseline statin dose or switching to rosuvastatin. In non-obese subjects (n = 342),
percent changes in LDL-C, total cholesterol, non-HDL-C, Apo B and Apo A-I were greater with ezetimibe/simvastatin
vs doubling the baseline statin dose or switching to rosuvastatin; and treatment with ezetimibe/simvastatin resulted
in greater changes in triglycerides vs rosuvastatin and HDL-C vs doubling the baseline statin dose. The safety
profiles were generally similar.
Conclusions: Regardless of baseline obesity status, switching to ezetimibe/simvastatin was more effective at
reducing LDL-C, total cholesterol, non-HDL-C, and Apo B vs doubling the baseline statin dose to simvastatin 40 mg
or atorvastatin 20 mg or switching to rosuvastatin 10 mg.
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The presence of diabetes and obesity is associated with
an increased risk of cardiovascular disease (CVD) [1-3].
Recommendations from the US, Canadian, and European
treatment guidelines focus on reducing LDL-C to <70 mg/
dL (<1.81 mmol/L) for high risk patients with diabetes and
cardiovascular disease (CVD) [4-6]. However, in obese in-
dividuals, when dyslipidemia is present it is often charac-
terized by decreased HDL-C and increased non-HDL-C,
triglycerides, apolipoprotein (Apo) B and small, dense LDL-
C particles, although often, relatively normal levels of LDL-* Correspondence: JBRcrsf@aol.com
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reproduction in any medium, provided the orC [7,8]. Likewise, the dyslipidemia associated with diabetes
is characterized by a similar lipid profile [9]. As a result, in-
dividuals with diabetes and/or obesity with dyslipidemia
may be undertreated even after intense lipid-lowering ther-
apy [9]. The use of combination therapies may be war-
ranted to achieve optimal lipid and lipoprotein levels, as
well as treatment targets for Apo B and non-HDL-C, as
recommended by the American Diabetes Association and
American College of Cardiology consensus statement for
patients with elevated cardiometabolic risk [9].
Clinical trials done in diabetic subjects have shown
that the combination of ezetimibe/simvastatin provides
additional lipid reductions over simvastatin and atorva-
statin monotherapy [10,11]. It has also been shown thattd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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those with diabetes, achieve target LDL-C levels when
treated with the combination of ezetimibe/simvastatin
10/40 mg compared with switching to atorvastatin 40 mg
or rosuvastatin 5–10 mg [12]. In addition, a pooled ana-
lysis of 27 studies that grouped subjects by baseline dia-
betic status (with or without diabetes) showed that the
lipid profile in subjects with diabetes improved to a greater
extent than in subjects without diabetes after treatment
with the combination of ezetimibe/statin [13]. However,
data assessing the effect of lipid lowering therapies in
obese and non-obese diabetic patients are limited.
The primary objective of this post hoc analysis was to
assess the consistency of treatment effect of switching to
ezetimibe/simvastatin 10/20 mg vs. doubling the base-
line statin dose to simvastatin 40 mg or atorvastatin
20 mg in subgroups of obese diabetic subjects (n = 466)
and non-obese diabetic subjects (n = 342) based on body
mass index (BMI) ≥30 kg/m2 or <30 kg/m2. The second-
ary objective was to perform a similar post hoc analysis as
the primary for the comparison of ezetimibe/simvastatin
10/20 mg vs switching to rosuvastatin 10 mg in the same
subgroups of subjects. Tolerability was also assessed.
Methods
This was a post hoc analysis of a randomized, double-
blind, 12-week study in subgroups of obese and non-obese
diabetic subjects based on body mass index ≥30 kg/m2
or <30 kg/m2 (Protocol 133; clinical trials registry NCT
00862251) [14]. The study was carried out between June
2009 and March 2011 in 86 centers in Austria, Bulgaria,
Chile, Costa Rica, Croatia, Egypt, Estonia, Germany,
Greece, Hungary, Italy, Latvia, Lithuania, Peru, Portugal,
and the United States and was conducted in conformance
with Good Clinical Practice standards and applicable coun-
try and/or local statutes and regulations regarding ethical
committee review, informed consent, and the protection of
human subjects participating in biomedical research.
Subjects
Eligible subjects were non-Asian males or females, ≥18
and <80 years, with type 1 or type 2 diabetes mellitus
(HbA1c ≤8.5%) and symptomatic/overt CVD who were
naïve to statin and/or ezetimibe or were taking a stable
dose of approved lipid-lowering therapy (simvastatin 10 or
20 mg; atorvastatin 10 mg; pravastatin 10, 20 or 40 mg;
fluvastatin 20, 40 or 80 mg, ezetimibe 10 mg; lovastatin
10, 20, 40 or 80 mg, or ezetimibe + fluvastatin 10 or
20 mg) and if needed, taking a stable anti-diabetic medica-
tion for 3 months prior to the screening visit. Subjects
must have been willing to maintain a cholesterol- and
glucose-lowering diet for the duration of the study. Prior
to randomization subjects were required to complete the
screening/stabilization period on simvastatin 20 mg oratorvastatin 10 mg with LDL-C ≥70 mg/dl (1.81 mmol/L)
and ≤160 mg/dl (4.14 mmol/L), alanine transaminase
(ALT) and aspartate aminotransferase (AST) ≤2.0 x upper
limit of normal (ULN) (no active liver disease), creatine
kinase (CK) ≤3 x ULN, and triglycerides ≤400 mg/dl
(4.52 mmol/L). Subjects were excluded if they were Asian,
since rosuvastatin prescribing information recommends a
5 mg starting dose for Asians. Subjects were also excluded
if they had uncontrolled endocrine or metabolic disease
that impacted lipids/lipoproteins, uncontrolled or recent-
onset diabetes, congestive heart failure, hypertension, di-
gestive disease/intestinal malabsorption, were taking agents
impacting lipids, potent CYP3A4 inhibitors, >1 quart/day
grapefruit juice, systemic corticosteroids, cyclosporine,
danazol or fusidic acid, agents increasing risk of myopathy,
or warfarin.Randomization and blinding
After a 6-week run-in period of simvastatin 20 mg or
atorvastatin 10 mg (baseline statin doses), subjects with
LDL-C ≥70 mg/dL (1.81 mmol/L) and ≤160 mg/dL
(4.14 mmol/L) were stratified according to their baseline
statin and randomized in a 2:1:2 ratio within strata to
ezetimibe/simvastatin 10/20 mg, doubling their baseline
statin, or rosuvastatin 10 mg for 6 weeks using an inter-
active voice response system. Subjects who met eligibility
criteria at the screening visit were provided with open-
label simvastatin 20 mg or atorvastatin 10 mg tablets. At
randomization, subjects were supplied in a double dummy
fashion with bottles of blinded ezetimibe/simvastatin 10/
20 mg or matching placebo and rosuvastatin 10 mg or
matching placebo. A blocked randomization was used
with a block size of 5. Subjects, investigators, and study
personnel involved in the study remained blinded during
the study period until the data were complete and clean
and a database lock was obtained.Efficacy endpoints
In this post hoc analysis, the primary evaluation was the
consistency of the treatment effect between ezetimibe/
simvastatin 10/20 mg vs. doubling the baseline statin
dose across subgroups (obese/non-obese) and the second-
ary evaluation was the consistency of the treatment effect
between ezetimibe/simvastatin 10/20 mg vs. rosuvastatin
10 mg across subgroups (obese/non-obese). Efficacy end-
points of interest were the percent change from baseline
in low density lipoprotein cholesterol (LDL-C), total cho-
lesterol, triglycerides, high-density lipoprotein cholesterol
(HDL-C), non-HDL-C, Apo B, Apo A-I, high-sensitivity
C-reactive protein (hs-CRP), LDL-C/HDL-C ratio, total
cholesterol/HDL-C ratio, non-HDL-C/HDL-C ratio, and
Apo B/Apo A-I ratio at Week 6. The percent of patients
achieving LDL-C <70 mg/dl (1.81 mmol/l), non-HDL-C
Figure 1 Flow of subjects through the study.
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was assessed at Week 6.
Safety endpoints
Prespecified adverse events (AEs) of interest were
gastrointestinal-related, gallbladder-related, allergic reac-
tion/rash-related, and hepatitis-related AEs; consecutive
elevations in alanine aminotransferase (ALT) / aspartate
aminotransferase (AST) ≥3 x ULN, ≥5 x ULN, and ≥10 x
ULN; consecutive elevations in ALT and/or AST ≥3 x
ULN, ≥5 x ULN and ≥10 x ULN, elevations in ALT or
AST ≥3 x ULN, elevations in CK ≥10 x ULN, elevations in
CK ≥10 x ULN with muscle symptoms, and elevations in
CK ≥10 x ULN with muscle symptoms that are considered
drug-related. In addition, the broad AE categories con-
sisting of the percentage of patients with any AE, a drug-
related AE, a serious AE, a serious drug-related AE, and
who discontinued due to an AE were assessed.
Statistics
The full analysis set (FAS), which included all random-
ized patients who took at least 1 dose of study drug and
had a baseline measurement, was used for the efficacy
analyses. The all-patients-as-treated (APaT) approach
was used for the safety analyses, and included all ran-
domized patients receiving ≥1 dose of study drug and all
safety data up to 14 days after the last intake of study
medication. At least 1 laboratory/vital sign measurement
was required subsequent to at least 1 dose of study treat-
ment for inclusion in the analysis of each specific param-
eter. The estimate of the within-group treatment effect, and
the between-group treatment effect with a nominal 95%
confidence interval for the efficacy variables was estimated
within each subgroup (i.e., obese/non-obese) using a con-
strained longitudinal data analysis model applied to each
subgroup separately, with terms for treatment, time, time-
by-treatment interaction, stratum, and time-by-stratum in-
teraction. As some deviation from normality was observed
for the percent change from baseline in LDL-C, a similar
post hoc sensitivity analysis on log-transformed data, as
done for the overall population, was performed to corrobor-
ate the main analysis on un-transformed data [14]. For AEs
of interest and broad AE categories, count and % of patients
with AEs were provided by treatment group within each
subgroup.
Results
The flow of subjects through the study is shown in
Figure 1. Of the 808 subjects that were randomized, 466
(57.7%) were included in the obese subgroup and 342
(42.3%) were included in the non-obese subgroup. Within
the obese subgroup, 181 (38.8%) were randomized to
ezetimibe/simvastatin, 93 (20.0%) were randomized to have
their statin dose doubled and 192 (41.2%) were randomizedto rosuvastatin 10 mg. Within the non-obese subgroup,
141 (41.2%) were randomized to ezetimibe/simvastatin, 69
(20.2%) were randomized to have their statin dose doubled
and 132 (38.6%) were randomized to rosuvastatin 10 mg.
Baseline demographics and clinical characteristics were
generally similar between obese and non-obese subjects
with a few exceptions (Table 1). In obese subjects, the mean
age (±SD) was ~63 (±8) years and the majority of subjects
were Caucasian in all 3 treatment groups. In the subgroup
of obese subjects, the rosuvastatin treatment group had a
slightly higher proportion of males (53.1%) compared with
the ezetimibe/simvastatin 10/20 mg (49.7%) and doubling
the statin dose (49.5%) treatment groups. In non-obese sub-
jects, the mean age (±SD) ranged from 64 (±9) years to 66
(±8) years and the majority of subjects were Caucasian in
all 3 treatment groups. There was a higher proportion of
Hispanics or Latinos in the non-obese subgroup (23.2% in
the doubling statin group, 24.2% in the rosuvastatin 10 mg
group and 31.9% in the ezetimibe/simvastatin 10/20 mg
group) compared with the obese subgroup (9.7% in the
doubling statin group, 10.5% in the ezetimibe/simvastatin
10/20 mg group and 11.5% in the rosuvastatin group).
Triglyceride levels were higher in obese subjects in all 3
treatment groups (median = 149 mg/dL, 136 mg/dL and
143.5 mg/dL in the ezetimibe/simvastatin 10/20 mg, doub-
ling the statin dose and rosuvastatin 10 mg groups, res-
pectively) compared with non-obese subjects (median =
126 mg/dL, 126 mg/dL and 132 mg/dL in the ezetimibe/
simvastatin 10/20 mg, doubling the statin dose and rosu-
vastatin 10 mg groups, respectively). Finally, hs-CRP levels
were higher in obese subjects compared with non-obese
subjects taking ezetimibe/simvastatin 10/20 mg (2.4 mg/L
vs 1.6 mg/L) and rosuvastatin 10 mg (2.6 mg/L vs 1.6 mg/
Table 1 Baseline demographics and clinical characteristics
EZ/Simva 10/20 mg Doubling statin dose Rosuvastatin 10 mg
Obese subjects n = 181 n = 93 n = 192
Sex, n (%)
Male 90 (49.7) 46 (49.5) 102 (53.1)
Female 91 (50.3) 47 (50.5) 90 (46.9)
Age, years Mean (SD) 63.3 (8.2) 63.5 (8.5) 63.3 (8.2)
Weight, kg Mean (SD) 99.3 (15.3) 96.2 (12.5) 96.5 (13.3)
Body Mass Index (BMI, kg/m2)
Mean (SD) 35.4 (4.3) 34.6 (3.7) 34.6 (3.7)
Race, n (%)
American Indian or Alaska Native 1 (0.6) 0 (0.0) 1 (0.5)
Black or African American 4 (2.2) 1 (1.1) 1 (0.5)
Multi-Racial 10 (5.5) 4 (4.3) 8 (4.2)
White 166 (91.7) 88 (94.6) 182 (94.8)
Ethnicity, n (%)
Hispanic or Latino 19 (10.5) 9 (9.7) 22 (11.5)
Not Hispanic or Latino 162 (89.5) 84 (90.3) 170 (88.5)
Clinical Characteristics, mg/dL Mean SD Mean SD Mean SD
LDL-C 97.9 22.4 99.3 22.0 95.7 19.1
Total cholesterol 179.0 30.4 180.5 27.0 178.3 24.2
Triglycerides* 149.0 74.4 136.0 77.2 143.5 74.4
HDL-C 48.6 11.5 51.0 11.6 47.8 10.7
Non-HDL-C 130.4 28.3 129.4 25.8 127.5 23.6
Apo B 101.6 19.8 101.7 17.7 100.0 18.6
Apo A-I 148.4 24.6 153.5 22.2 147.6 22.0
hs-CRP*, mg/L 2.4 2.9 1.9 3.2 2.6 3.7
Non-obese subjects n = 141 n = 69 n = 132
Sex, n (%)
Male 70 (49.6) 34 (49.3) 80 (60.6)
Female 71 (50.4) 35 (50.7) 52 (39.4)
Age, years Mean (SD) 65.2 (9.3) 66.2 (7.9) 64.0 (8.6)
Weight, kg Mean (SD) 73.5 (11.0) 76.3 (11.5) 76.3 (11.5)
Body mass index (BMI, kg/m2)
Mean (SD) 35.4 (4.3) 34.6 (3.7) 34.6 (3.7)
Race, n (%)
American Indian or Alaska Native 3 (2.1) 2 (2.9) 4 (3.0)
Black or African American 1 (0.7) 1 (1.4) 1 (0.8)
Multi-Racial 23 (16.3) 7 (10.1) 16 (12.1)
White 114 (80.9) 59 (85.5) 111 (84.1)
Ethnicity, n (%)
Hispanic or Latino 45 (31.9) 16 (23.2) 32 (24.2)
Not Hispanic or Latino 96 (68.1) 53 (76.8) 100 (75.8)
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Table 1 Baseline demographics and clinical characteristics (Continued)
Clinical characteristics, mg/dL Mean SD Mean SD Mean SD
LDL-C 100.1 21.6 94.7 20.2 99.9 20.5
Total cholesterol 180.5 30.9 173.0 26.3 178.7 28.7
Triglycerides* 126.0 65.1 126.0 51.2 132.0 76.3
HDL-C 52.6 15.8 50.6 12.7 50.5 13.3
Non-HDL-C 127.9 26.9 122.4 25.3 128.2 26.4
Apo B 101.7 20.4 98.9 20.1 101.0 20.0
Apo A-I 152.7 32.9 153.1 28.2 149.4 27.3
hs-CRP*, mg/L 1.6 2.9 2.0 2.2 1.6 2.3
*Data for TG and hs-CRP are presented as median and robust standard deviation.
EZ Ezetimibe, Simva Simvastatin.
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bled (1.9 mg/L vs 2.0 mg/L).
Regardless of baseline obesity status (obese/non-obese),
in this population of high risk diabetic subjects, switching
to ezetimibe/simvastatin 10/20 mg generally resulted in
numerically greater changes in LDL-C compared with
doubling the baseline statin dose or switching to rosu-
vastatin, though the treatment effect was smaller for the
comparison of ezetimibe/simvastatin 10/20 mg vs. rosuva-
statin 10 mg in the obese subgroup (Figure 2). In obese
subjects LS mean percent changes from baseline in LDL-
C were −21.6%, -10.7%, and −20.7% in the ezetimibe/sim-
vastatin 10/20 mg group, in the doubling statin group, and
in the rosuvastatin 10 mg group, respectively. In non-
obese subjects, LS mean percent changes from baseline in
LDL-C were −25.2%, -4.9%, and −17.4% in the ezetimibe/
simvastatin 10/20 mg group, in the doubling statin group,
and in the rosuvastatin 10 mg group, respectively. The re-
sults of the post hoc sensitivity analysis on log-transformed
data were consistent with those of the main analysis on
un-transformed data; however, for the comparison vs.Figure 2 Least squares mean percent change from baseline in
LDL-C in obese and non-obese subjects after 6 weeks of
treatment. Bars represent standard error. (FAS population).rosuvastatin in obese subjects, the magnitude of the LDL-
C difference in the post hoc sensitivity analysis was some-
what higher compared with the main analysis (−3.2% in
this analysis vs. -0.9% in the main analysis).
Achievement of specified lipid targets is shown in
Figure 3. In obese and non-obese subjects, more sub-
jects achieved the specified LDL-C targets of <70 mg/dL
when treated with ezetimibe/simvastatin 10/20 mg (non-
obese: 57.4%; obese: 52.2%) compared with doubling the
baseline statin dose to simvastatin 40 mg or atorvastatin
20 mg (non-obese: 29.0%; obese: 25.6%) or switching to
rosuvastatin 10 mg (non-obese: 32.5%; obese: 49.2%). Sim-
ilarly, more subjects achieved non-HDL-C <100 mg/dL
when treated with ezetimibe/simvastatin 10/20 mg (non-
obese: 63.2%; obese: 52.2%) compared with doubling the
baseline statin dose to simvastatin 40 mg or atorvastatin
20 mg (non-obese: 31.9%; obese: 30.0%) or switching
to rosuvastatin 10 mg (non-obese: 43.7%; obese: 46.0%;
Figure 3). Finally, a greater percentage of subjects achieved
Apo B <80 mg/dL when treated with ezetimibe/simvastatin
10/20 mg (non-obese: 50.0%; obese: 45.8%) compared with
doubling the baseline statin dose to simvastatin 40 mg or
atorvastatin 20 mg (non-obese: 31.9%; obese: 25.6%) or
switching to rosuvastatin 10 mg (non-obese: 39.2%; obese:
38.1%; Figure 3).
In both obese and non-obese subjects, treatment with
ezetimibe/simvastatin 10/20 mg resulted in numerically
greater changes in total cholesterol, non-HDL-C, and
Apo B compared with doubling the baseline statin dose to
simvastatin 40 mg or atorvastatin 20 mg or vs switching to
rosuvastatin 10 mg (Table 2 and Figures 4a and 4b). How-
ever, changes in HDL-C and Apo A-I appeared to be simi-
lar between treatments in obese subjects (Figure 4a). In
non-obese subjects (Figure 4b) changes in triglycerides
were numerically greater in the ezetimibe/simvastatin 10/
20 treatment group compared with the rosuvastatin 10 mg
group, while the subjects whose baseline statin dose
was doubled showed similar decreases to subjects treated
Figure 3 Percent of subjects achieving specified targets after 6 weeks of treatment (FAS population).
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jects, changes in HDL-C were similar between treatment
groups, and increases in Apo A-I were greater in the
ezetimibe/simvastatin 10/20 mg vs the doubling the base-
line statin dose group (Figure 4b). In both obese and non-
obese subjects changes in hs-CRP were numerically greater
with rosuvastatin 10 mg vs ezetimibe/simvastatin 10/20 mg
(Figures 4a and 4b). In both obese and non-obese subjects,
ezetimibe/simvastatin 10/20 mg was more effective at im-
proving lipid ratios compared with doubling the baseline
statin dose to simvastatin 40 mg or atorvastatin 20 mg, al-
though the changes were similar to those of rosuvastatin
10 mg-treated subjects in both obese and non-obese sub-
jects (Figures 5a and 5b).
The safety and tolerability profiles were generally simi-
lar between treatment groups (Table 3). In the group
of obese subjects, 9.9%, 9.7% and 6.8% of subjects ex-
perienced ≥1 AE in the ezetimibe/simvastatin group,
in the doubling the statin dose group, and the rosuva-
statin group, respectively. Three subjects each from the
ezetimibe/simvastatin and the doubling the statin dose
group discontinued due to an AE, and 2 were due to
drug-related AEs. One subject experienced consecutive
elevations in AST >3 X ULN in the rosuvastatin treat-
ment group. There were 4 (2.2%), 1 (1.1%) and 3 (1.6%)Table 2 Least Squares mean percent change from baseline (9
LDL-C TC TG
Non-obese EZ/Simva (n = 77) −25.2 −13.9 −4.8
Doubling statin (n = 42) −4.9 −4.1 −5.3
Rosuva 10 (n = 42) −17.4 −9.4 −2.0
Obese EZ/Simva (n = 237) −21.6 −12.7 −6.1
Doubling statin (n = 117) −10.7 −5.3 −0.8
Rosuva 10 (n = 249) −20.7 −11.4 −4.2reports of gastrointestinal-related AEs in subjects taking
ezetimibe/simvastatin group, in subjects who doubled
their statin dose, and in the rosuvastatin group, respec-
tively; and 2 reports (1.0%) of hepatitis-related AEs in
rosuvastatin treated subjects. In the non-obese subjects,
10.7%, 5.8% and 11.5% of subjects experienced ≥1 AE in
the ezetimibe/simvastatin group, in the doubling the sta-
tin dose group, and in the rosuvastatin group, respect-
ively. Four subjects from the ezetimibe/simvastatin
group and 1 subject from the rosuvastatin group discon-
tinued due to an AE and 1 was a drug related AE in the
ezetimibe/simvastatin group. There were no reports of
elevations in liver enzymes in the group of non-obese
subjects. There were 6 (4.3%) and 4 (3.1%) reports of
gastrointestinal-related AEs in subjects taking ezetimibe/
simvastatin and in subjects taking rosuvastatin, respec-
tively; and 2 reports (1.5%) of hepatitis-related AEs in
rosuvastatin-treated subjects. No clinically meaningful
differences in change from baseline in blood pressure
between the treatment groups were observed in any
subgroup.
Discussion
There have been relatively few studies that have assessed
the comparative efficacy of the combination of ezetimibe/5% confidence interval) in lipids, lipoproteins and hs-CRP
HDL-C non-HDL-C Apo B Apo A-I hs-CRP
1.8 −19.9 −16.6 2.0 −7.1
−0.2 −4.8 −5.6 −2.3 −3.7
2.6 −13.9 −11.6 1.3 −10.1
1.2 −17.3 −13.7 −0.4 −1.5
1.8 −8.2 −8.0 0.0 1.1
1.6 −16.1 −12.3 0.6 −9.7
ab
Figure 4 Least squares mean percent change from baseline in lipids, lipoproteins and hs-CRP after 6 weeks of treatment. Bars represent
standard error. (FAS population). a. Obese subjects. b. non-obese subjects.
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same trial. This is the first report of the consistency of
treatment effect of all three of these high-potency lipid-
lowering therapies between subgroups of obese and non-
obese diabetic patients in the same trial. With obesity
reaching global epidemic proportions and its strong rela-
tionship to the development of CVD and atherogenic
dyslipidemia, it is important to understand the potential
utility of lipid lowering drugs in this population. In this
post hoc analysis of subgroups of obese and non-obese
diabetic subjects, treatment with ezetimibe/simvastatin
10/20 mg resulted in numerically greater reductions in
LDL-C compared with rosuvastatin 10 mg only in the
non-obese subjects, while the combination of ezetimibe/
simvastatin 10/20 mg resulted in greater changes in LDL-
C levels compared with doubling the statin dose in sub-
jects in both subgroups regardless of baseline obesity
status (obese/non-obese). In addition, a higher proportion
of subjects attained all 3 specified treatment targets (LDL-
C, non-HDL-C and Apo-B) with ezetimibe/simvastatin10/20 mg treatment vs doubling the statin dose to atorva-
statin 20 mg or simvastatin 40 mg and vs rosuvastatin
10 mg in both subgroups of obese and non-obese subjects.
The overall safety and tolerability profile appeared gener-
ally comparable and consistent across subgroups and all
treatment groups.
The dyslipidemia profile typically observed in obese
and diabetic individuals is generally similar and includes
high triglycerides (≥200 mg/dL), non-HDL-C, and Apo
B levels, increased levels of small, dense LDL-C particles,
although often, relatively normal levels of LDL-C, and
low HDL-C levels (<40 mg/dL in men and <50 mg/dL in
women) [7,8]. As expected, subjects in the obese sub-
group had higher mean baseline triglycerides than sub-
jects in the non-obese subgroup; however, these mean
levels were lower than the 200 mg/dL level specified by
the NCEP ATP III guidelines that would define patients
as having mildly or moderately elevated triglycerides [4].
In addition, they did not have low mean HDL-C levels
as would be expected based on typical dyslipidemia
ab
Figure 5 Least squares mean percent change from baseline
in lipid ratios after 6 weeks of treatment. Bars represent
standard error. (FAS population). a. obese subjects. b.
non-obese subjects.
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levels in the obese subjects were comparable to those of
the non-obese subjects, with mean levels already at or
below 100 mg/dL in all treatment groups, but not
reaching the target level of <70 mg/dL as specified by
the NCEP ATP III guidelines for very high risk individuals.
It is important to note that these baseline numbers reflect
treated baseline levels, likely resulting from pre-study
treatment and/or the 6-week run-in period during which
subjects were treated with a starting dose of simvastatin
(20 mg) or atorvastatin (10 mg) and during which they
agreed to maintain an approved cholesterol- and glucose-
lowering diet. This pre-study treatment may be why the
typical dyslipidemia profile was not observed.
The post hoc analysis results from the subgroup of
obese subjects were generally consistent with those of theprespecified analysis results from the overall population
with regard to percent change from baseline in LDL-C
[14]. Specifically, in the overall population, treatment with
the combination of ezetimibe/simvastatin resulted in sig-
nificantly greater reductions in LDL-C and other lipids
compared with doubling the baseline statin dose to ator-
vastatin 20 mg or simvastatin 40 mg, but not compared
with rosuvastatin 10 mg. However, in the subgroup of
non-obese subjects in the current post hoc analysis,
greater reductions in LDL-C were observed in favor of
ezetimibe/simvastatin 10/20 mg vs doubling the baseline
statin dose to atorvastatin 20 mg or simvastatin 40 mg
and vs rosuvastatin 10 mg. These results are consistent
with the sensitivity analyses of the overall population
which showed statistically significant differences between
the combination treatment and rosuvastatin 10 mg (−27.58
vs −22.20; p = 0.002). Moreover, the current sensitivity ana-
lysis results are consistent not only with the current ex-
ploratory analysis, but also with the primary analysis;
however, for the ezetimibe/simvastatin 10/20 mg vs. ro-
suvastatin 10 mg comparison, the magnitude of the differ-
ence appeared to be somewhat higher compared with the
main analysis. A previous post hoc analysis conducted in
obese and non-obese subjects reported greater reductions
with ezetimibe/simvastatin 10/20 mg vs. rosuvastatin
10 mg in both subgroups, however, those patients were
not all diabetic [15]. In addition, the results of a study by
Furman and colleagues in high risk patients (BMI = 30–
31 kg/m2) who had not achieved LDL-C <100 mg/dL while
treated with simvastatin demonstrated significantly greater
reductions in LDL-C with the combination of ezetimibe/
simvastatin vs rosuvastatin and vs atorvastatin (p <0.05)
using average doses of 9/64 mg ezetimibe/simvastatin,
18 mg rosuvastatin, and 68 mg atorvastatin, which is con-
sistent with the numerically greater reductions in most
lipids vs doubling the statin dose to simvastatin 40 mg or
atorvastatin 20 mg or vs rosuvastatin 10 mg observed in
the current analysis [16]. One explanation for the incon-
sistencies between this group of subjects and those in pre-
vious studies may be differences in metabolism due to the
presence of diabetes, which has been associated with high
cholesterol synthesis and reduced cholesterol absorption
efficiency regardless of obesity [17]. Larger trials to com-
pare obese and non-obese diabetic patients are needed to
fully assess these questions.
Although there is resounding evidence that LDL-C
lowering reduces cardiovascular risk, there are also data to
demonstrate that the typical dyslipidemia profile observed
in diabetic patients, which is shared by obese patients,
often results in residual risk even after LDL-C targets are
achieved. Consequently, it is essential to consider second-
ary lipoprotein targets to reduce the atherogenic burden in
diabetic patients once they have reached their individual
LDL-C goal. Specifically, elevated Apo B and non-HDL-C
Table 3 Summary of safety data (APaT population)
Obese subjects Non-obese subjects
EZ/Simva 10/
20 mg (N = 181)
Doubling statin
dose (N = 93)
Rosuvastatin
10 mg (N = 192)
EZ/Simva 10/
20 mg (N = 140)
Doubling statin
dose (N = 69)
Rosuvastatin
10 mg (N = 131)
n (%) n (%) n (%) n (%) n (%) n (%)
≥1 AE 18 (9.9) 9 (9.7) 13 (6.8) 15 (10.7) 4 (5.8) 15 (11.5)
Drug-related AE 6 (3.3) 2 (2.2) 2 (1.0) 2 (1.4) 0 (0.0) 0 (0.0)
Serious AE 0 (0.0) 1 (1.1) 2 (1.0) 2 (1.4) 0 (0.0) 0 (0.0)
Serious drug-related AE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Death 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Discontinued due to
AE 3 (1.7) 3 (3.2) 0 (0.0) 4 (2.9) 0 (0.0) 1 (0.8)
Drug-related AE 2 (1.1) 2 (2.2) 0 (0.0) 1 (0.7) 0 (0.0) 0 (0.0)
Serious AE 0 (0.0) 1 (1.1) 0 (0.0) 1 (0.7) 0 (0.0) 0 (0.0)
AEs of special interest
Allergic reaction or rash 1 (0.6) 0 (0.0) 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.8)
Gastrointestinal-related 4 (2.2) 1 (1.1) 3 (1.6) 6 (4.3) 0 (0.0) 4 (3.1)
Hepatitis-related 0 (0.0) 0 (0.0) 2 (1.0) 0 (0.0) 0 (0.0) 2 (1.5)
Laboratory AEs of special
interest
N = 177 N = 89 N = 188 N = 131 N = 69 N = 125
ALT ≥3xULN, consecutive* 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0 0 (0.0) 0 (0.0)
AST ≥3xULN, consecutive* 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0 0 (0.0) 0 (0.0)
ALT and/or AST ≥3xULN,
consecutive*
0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0 0 (0.0) 0 (0.0)
CK ≥10xULN, single 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0 0 (0.0) 0 (0.0)
*Consecutive includes those patients with (a) measurement ≥3 x ULN observed at 2 or more consecutive visits (b) a single, last measurement ≥3 x ULN,
or (c) a measurement ≥3 x ULN followed by a measurement < 3 x ULN that was taken more than 2 days after the last dose of study medication.
AE adverse event, ALT alanine aminotransferase, AST aspartate aminotransferase, CK creatine kinase, EZ ezetimibe, Simva Simvastatin, ULN upper limit
of normal.
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patients [4,9]. In this study, regardless of baseline obesity
status (obese/non-obese), the combination of ezetimibe/
simvastatin treatment resulted in higher percentages of
diabetic patients achieving not only the aggressive LDL-C
target of <70 mg/dL, but also non-HDL-C <100 mg/dL
and Apo-B <80 mg/dL treatment targets compared with
doubling the baseline statin dose and compared with
rosuvastatin 10 mg. This result is consistent with a previ-
ous post hoc analysis of obese and non-obese subjects (of
which only 1/3 were diabetic) in which higher percentages
of patients achieved specified LDL-C, non-HDL-C and Apo
B levels when treated with combination ezetimibe/simva-
statin compared with rosuvastatin monotherapy [15].
The safety and tolerability profiles were generally consis-
tent between treatments and between subgroups, although
slightly more subjects taking ezetimibe/simvastatin 10/
20 mg discontinued due to AEs compared with the other
treatment groups. Previous trials comparing the safety
profile of ezetimibe combined with simvastatin vs statins,
including a post hoc analysis in obese and non-obesesubjects do not suggest that there are significant tolerabil-
ity differences between these treatments [15,18]; however,
the use of the highest dose (80 mg) of simvastatin has
been restricted by the US Food and Drug Administration
due to the higher risk of myopathy/rhabdomyolysis [19].
Moreover, previous studies in high-risk diabetic subjects
have not indicated tolerability issues with the combination
treatment [10,11].
This study was an exploratory, post hoc analysis and
did not include statistical comparisons, nor multiplicity
adjustments. Moreover, the study was not powered to de-
tect very rare adverse events and was of relatively short
duration. Therefore, the efficacy and safety results should
be interpreted with some caution.
These results suggest that regardless of baseline obes-
ity status (obese/non-obese), switching to combination
ezetimibe/simvastatin 10/20 mg provides a well-tolerated
lipid-lowering effect in diabetic hypercholesterolemic sub-
jects who have not achieved a goal of LDL-C <70 mg mg/
dl (1.81 mmol/L) while on simvastatin 20 mg or atorva-
statin 10 mg.
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